Cutaneous reactions following CoronaVac COVID-19 vaccination: a case series of six healthcare workers from a single centre
| Autor: | Nilsel Ilter, Murat Orhan Öztaş, Elçin Akdas, Ozlem Erdem, Betul Ogut |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Emergency Use Authorization COVID-19 Vaccines Coronavirus disease 2019 (COVID-19) business.industry SARS-CoV-2 Public health Health Personnel Vaccination COVID-19 Dermatology Letter To The Editor Letters To The Editor Clinical trial Infectious Diseases Health care Pandemic Emergency medicine Inactivated vaccine Medicine Humans business |
| Zdroj: | Journal of the European Academy of Dermatology and Venereology |
| ISSN: | 1468-3083 |
| Popis: | The significant impact of the COVID-19 pandemic on public health, the economy and society required rapid action and the development of vaccines in an unprecedented time frame. While traditional vaccine development may take 15 years or more, vaccine development for SARS-CoV-2 has been reduced to 12-18 months with an accelerated timeline.[1] Phase 1/2 clinical trials of the inactivated vaccine candidate CoronaVac COVID-19 vaccine showed that this vaccine is safe and tolerable, and phase 3 clinical trials were conducted in Brazil, Turkey and Indonesia.[2] Announced emergency use authorization for CoronaVac on January 13, 2021 in Turkey.[3] Vaccination was initiated primarily in healthcare workers and higher risk groups. The vaccine was given in two doses (days 0 and 28). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text